Role of olverembatinib with vindesine or vincristine and prednisolone in the major molecular remission for newly diagnosed adult philadelphia chromosome-positive acute lymphoblastic leukemia in the induction therapy: A single-arm, multi-center, prospective study.

Role of olverembatinib with vindesine or vincristine and prednisolone in the major molecular remission for newly diagnosed adult philadelphia chromosome-positive acute lymphoblastic leukemia in the induction therapy: A single-arm, multi-center, prospective study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059682

Enrollment

Unknown

Registered

2022-05-07

Start date

2022-04-23

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

philadelphia chromosome-positive acute lymphoblastic leukemia

Interventions

Exprerimental group:Orebatinib with vindesine and prednisolone

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Sex is not limited to adults older than 18 years old ph+ALL; 2. There is no serious damage to the function of important organs of the whole body, ECOG = 2 points; 3. Subjects volunteered and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have serious cardiac, renal or hepatic insufficiency; 2. Those with other malignant tumors that need treatment; 3. The patient has clinical symptoms of brain dysfunction or serious mental illness, and cannot understand or follow the research protocol; 4. Those who cannot follow up as scheduled; 5. Subjects who cannot guarantee to complete the necessary treatment plan and follow-up observation.

Design outcomes

Primary

Measure	Time frame
Major Molecualr remission;	—

Secondary

Measure	Time frame
complete remission;Rate of MRD negativity;complete molecular remission;Advert effect;	—

Countries

China

Contacts

Public ContactCheng Zhang

Xinqiao Hospital of Army Medical University

1764180534@qq.com+86 23 68774209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026